Alpha 2.0
Login Register
» Authors » Hidetoshi Takahashi

Hidetoshi Takahashi

Explore the profile of Hidetoshi Takahashi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 276
Citations 2477
Followers 0
Related Specialties
Dermatology
Neurology
Psychiatry
Top 10 Co-Authors
Hajime Iizuka
Akemi Ishida-Yamamoto
Masaru Honma
Takayuki Nakahachi
Masatoshi Takeda
Masao Iwase
Yoko Kamio
Toru Nakazawa
Ryouhei Ishii
Yoshio Hashimoto
Published In
J Dermatol
J Dermatol Sci
PLoS One
Arch Dermatol Res
J Invest Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Association between maternal history of mental illness and neurodevelopment of children during the first 3 years: The Japan Environment and Children's Study
Ohara N, Mitsuda N, Yamasaki K, Eitoku M, Suganuma N, Komatsu S, et al.
PCN Rep . 2025 Feb; 4(1):e70073. PMID: 39980859
Aim: The impact of maternal mental illness on children's neurodevelopment has been insufficiently investigated, particularly in large populations. In this study, we examined the association between maternal mental health history...
2.
Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study
Ackerman L, Schlosser B, Zhan T, Prajapati V, Fretzin S, Takahashi H, et al.
J Am Acad Dermatol . 2025 Feb; PMID: 39909350
Background: Hidradenitis suppurativa is a disabling inflammatory skin disease. Objective: To investigate the efficacy and safety of upadacitinib, a selective Janus kinase inhibitor. Methods: In this phase 2, randomized, placebo-controlled,...
3.
Influences of upper limb orthosis on trunk muscle activity during static and dynamic sitting tasks for hemiparetic stroke
Fukata K, Chiba Y, Shida K, Natsuaki S, Kakinuma R, Izumi N, et al.
Clin Biomech (Bristol) . 2025 Jan; 122:106439. PMID: 39870048
Background: We aimed to clarify the immediate effect of wearing the Omo Neurexa upper limb suspended orthosis (Ottobock Japan, Tokyo, Japan) on trunk muscle activity during seated tasks. Methods: Fifteen...
4.
Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
Katoh N, Tanaka A, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, et al.
Curr Med Res Opin . 2024 Dec; 41(1):1-12. PMID: 39625230
Objective: To evaluate efficacy and safety of lebrikizumab combined with topical corticosteroids (TCS) in Japanese patients with moderate-to-severe atopic dermatitis (AD). Methods: Phase 3, randomized, double-blind, placebo-controlled study (ADhere-J; NCT04760314)...
5.
Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week, randomized, double-blind, placebo-controlled phase III trial in Japan (ADhere-J)
Katoh N, Tanaka A, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, et al.
Br J Dermatol . 2024 Oct; PMID: 39442013
Background: Moderate-to-severe atopic dermatitis (AD) impacts patients' quality of life (QOL). More treatment options are urgently needed to manage this chronic disease. Lebrikizumab is a monoclonal antibody that binds to...
6.
Reduced multiscale complexity of daily behavioral dynamics in autism spectrum disorder
Nakamura T, Sumiyoshi T, Kamio Y, Takahashi H
PCN Rep . 2024 Sep; 3(4):e70016. PMID: 39329059
Aim: Autism spectrum disorder (ASD) is difficult to diagnose objectively due to its heterogeneous and complex manifestations. This study aimed to objectively characterize the behavioral phenotypes of ASD children by...
7.
Long term safety and efficacy of ligelizumab in the treatment of Japanese patients with chronic spontaneous urticaria
Takahashi H, Fukunaga A, Hayama K, Sasajima T, Fujishige A, Ichishita R, et al.
Allergol Int . 2024 Sep; 74(1):136-143. PMID: 39327219
Background: In Japan, urticaria is a common skin disorder with chronic spontaneous urticaria (CSU) being the most frequent subtype. This study evaluated the safety of ligelizumab (anti-IgE monoclonal antibody) in...
8.
Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis
Tanaka A, Igawa K, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, et al.
Acta Derm Venereol . 2024 Sep; 104:adv34375. PMID: 39248292
Lebrikizumab has previously demonstrated efficacy in Phase 3 trials: ADvocate1 and ADvocate2 (as monotherapy), ADhere, and ADhere-J (in combination with topical corticosteroids). Here, the impact of lebrikizumab combined with low-...
9.
Predictors of probable attention deficit hyperactivity disorder in elderly patients with mild cognitive impairment visiting a memory clinic
Nagano S, Kamimura N, Sota S, Takahashi H, Suganuma N, Kazui H
PCN Rep . 2024 Jun; 2(2):e104. PMID: 38868147
Aim: Characteristics of attention deficit hyperactivity disorder (ADHD) that persist into old age are often confused with symptoms of mild cognitive impairment (MCI), and the actual rate of probable ADHD...
10.
Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from PROMINENT
Abe M, Okubo Y, Takahashi H, Endo K, Chaudhari S, Deignan C, et al.
Dermatol Ther (Heidelb) . 2024 May; 14(6):1587-1597. PMID: 38801606
Introduction: Psoriasis involvement in special areas (e.g., scalp or nails) is associated with a great disease burden yet it is often inadequately treated with topical treatments. The efficacy and tolerability...